A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Locally Advanced or Metastatic Breast Cancer Clinical Trial

Official title:
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer

Status Recruiting

Clinical Trial Summary

This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer (metastatic or locally advanced disease not amenable to curative treatment) who have not previously received a systemic non-hormonal anti-cancer therapy in the advanced setting.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Breast Neoplasms
Locally Advanced or Metastatic Breast Cancer

Clinical Trial Details

NCT number	NCT05296798
Study type	Interventional
Source	Hoffmann-La Roche
Contact	Reference Study ID Number: WO43571 https://forpatients.roche.com
Phone	888-662-6728 (U.S. Only)
Email	global-roche-genentech-trials@gene.com
Status	Recruiting
Phase	Phase 3
Start date	July 4, 2022
Completion date	September 30, 2032

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05860465` - Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer	Phase 2/Phase 3
Active, not recruiting	`NCT03781063` - Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Phase 2
Recruiting	`NCT05054751` - GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer	Phase 3
Completed	`NCT03027245` - Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
Not yet recruiting	`NCT05172518` - Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer	Phase 3
Recruiting	`NCT05430399` - Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer	Phase 3
Terminated	`NCT00634088` - Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer	Phase 1
Not yet recruiting	`NCT05403333` - Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer	Phase 2
Completed	`NCT03437083` - A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
Recruiting	`NCT05744687` - Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer	Phase 2/Phase 3
Active, not recruiting	`NCT06439771` - A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC	Phase 2
Withdrawn	`NCT05212701` - To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer	Phase 2